ArticleFrontiers in endocrinology2026
Predictive value of sperm DFI, ROS, and MMP for
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the levels of sperm DNA fragmentation index (DFI), reactive oxygen species (ROS), and mitochondrial membrane potential (MMP) in asthenozoospermic patients and assess their predictive value for Methods: This retrospective cohort study included 320 men with asthenozoospermic patients and 100 with normal semen parameters, assessed between January 2023 and June 2024. Of these, 143 couples undergoing IVF-embryo transfer were analyzed for outcomes. Semen samples were evaluated for conventional parameters, DFI, ROS, and MMP. Patients were stratified by DFI and MMP thresholds, and a combined DFI/MMP group was analyzed. Fertilization rate, cleavage rate, high-quality embryo rate, blastocyst formation rate, clinical pregnancy rate, miscarriage rate, and live birth rates were recorded. Multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were performed. Results: Asthenozoospermic patients showed significantly higher DFI and ROS, and lower MMP compared to controls, with these parameters correlating to asthenozoospermia severity. DFI and MMP were identified as independent predictors of clinical pregnancy rate via multivariate logistic regression. The high DFI group had significantly lower fertilization, pregnancy, and live birth rates than the low DFI group, while the high MMP group demonstrated superior outcomes across all metrics compared to the low MMP group. The low DFI/high MMP group achieved the best results, exhibiting significantly higher fertilization, pregnancy, and live birth rates than the high DFI/low MMP group. ROC curve analysis indicated that the combination of DFI and MMP provided greater predictive power for clinical pregnancy (AUC = 0.771) than DFI (AUC = 0.643) or MMP (AUC = 0.651) alone. Conclusion: Sperm DFI and MMP are confirmed as independent and clinically significant predictors of clinical pregnancy in asthenozoospermic patients undergoing IVF treatment. The combined assessment of DFI and MMP offers superior predictive utility for IVF pregnancy outcomes compared to the assessment of either marker alone. These findings underscore the critical role of these sperm quality parameters in assessing reproductive potential and suggest significant clinical utility for guiding patient management and optimizing treatment strategies in assisted reproductive technologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.